TOXICOLOGICAL STUDIES ON A NEW MACROLIDE ANTIBIOTIC, MIDECAMYCIN ACETATE (MIOCAMYCIN)

  • YOKOTA MASAYUKI
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • TAKEDA UETO
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • ODAKI MASUZO
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • SASAKI HITOSHI
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • NIIZATO TETSUTARO
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • KAWAOTO HARUO
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • WATANABE HIROSHI
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • ITOH TAKASHI
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • ISHIWATARI NOBUYOSHI
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.
  • KOEDA TAKEMI
    Laboratory of Safety Evaluation, Central Research Laboratories, Meiji Seika Kaisha, Ltd.

Bibliographic Information

Other Title
  • CHRONIC TOXICITY IN RATS

Search this article

Description

Miocamycin (MOM) is a derivative of midecamycin (MDM), a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens1, 2). Its chemical structure is shown in Fig. 1. It is reported that MOM has the most interesting antibacterial properties among the known macrolide antibiotics3, 4). It has been known that the maximum tolerable dosage level of MOM, non-crystalline solid, was 1, 000 mg/kg in male and female rats when it was orally administered once daily for 5 weeks at daily dosage levels of 1, 000, 2, 000 and 4, 000 mg/kg as previously reported5).<BR>The objective of this study was to examine toxicological effects in male and female rats after repeated oral administration of MOM, non-crystalline solid, for 26 weeks at daily dosage levels of 62. 5, 125, 250, 500 and 1, 000mg/kg.

Journal

Details 詳細情報について

  • CRID
    1390282680471213184
  • NII Article ID
    130004394126
  • DOI
    10.11553/antibiotics1968b.37.1355
  • COI
    1:CAS:528:DyaL2MXitVA%3D
  • ISSN
    21865477
    03682781
  • PubMed
    6333530
  • Text Lang
    en
  • Article Type
    journal article
  • Data Source
    • JaLC
    • PubMed
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top